Glass House Brands Inc. is a vertically integrated cannabis company focused on the California market. The business cultivates cannabis at scale in large greenhouse facilities, manufactures consumer packaged goods, and distributes through both wholesale channels and its own retail dispensaries. Its brand portfolio includes Glass House Farms, PLUS, Allswell, and Mama Sue Wellness, spanning flower, concentrates, vape products, and edibles.
The company was founded in 2015, is headquartered in Long Beach, California, and is listed on the New York Stock Exchange. Investors follow the stock for its low-cost, high-volume cultivation strategy, its pursuit of production-cost reductions, and its positioning for potential federal cannabis reform, including the rescheduling of cannabis to Schedule III. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, GLAS has declined approximately 49.4%, from a closing price of $2.33 on October 21, 2026, to roughly $1.18. The move has been punctuated by sharp single-day declines on elevated volume, signaling sustained selling pressure rather than a gradual drift lower.
The quarterly trend is even more pronounced. In late August, the stock traded near $9.50–$10.00; it has since fallen roughly 88% to about $1.18. This places GLAS near the lower end of its 52-week range of approximately $1.06 to $13.93, and well below its 50-day moving average of around $4.39.
Several company-specific developments drove the decline. Third-quarter results reported on November 16, 2026, showed strong top-line growth and record output, with revenue of $56.8 million versus $47.0 million in the prior quarter, and record biomass production of roughly 319,000 pounds. Production costs fell to about $109 per pound.
However, the quarter also revealed deteriorating profitability: the average selling price dropped to about $151 per pound from $211 in the prior quarter, gross margin narrowed to 26% from 34%, adjusted EBITDA fell to $0.8 million from $5.7 million, and the company posted a loss of $0.14 per share, slightly missing estimates. A trim-heavy sales mix of roughly 63% amplified the pricing pressure.
Separately, the company announced on November 11 that auditor BDO USA had resigned at the company's request, with Macias Gini & O'Connell LLP reappointed. The change followed the June 2026 deconsolidation of Glass House's recreational retail business. In November, a law firm announced an investigation into potential securities claims related to the auditor resignation and disclosures around the retail deconsolidation. Analyst actions added to the pressure: Zacks downgraded the stock to "strong sell," while Lake Street maintained a buy rating but cut its price target from $7.00 to $3.00.
The broader multi-month decline reflects a combination of structural and governance concerns. The separation of the retail business, repeated auditor changes, and associated disclosure questions undermined confidence in the company's reporting and governance. At the same time, the company funded greenhouse expansion largely through an at-the-market equity program, selling millions of shares at prices well above current levels, which diluted existing shareholders.
Declining wholesale cannabis prices continued to compress margins even as output grew, and the company paused its hemp operations amid regulatory uncertainty. Leadership changes, including a planned CFO retirement and a board resignation, added to the sense of transition. Taken together, these factors reset investor expectations for a company whose equity now sits beneath substantial debt and preferred-dividend obligations. From what I see, this combination of issues has been particularly difficult for the market to overlook.
Looking ahead, investors are likely to focus on whether the company can sustain its cost-per-pound reductions while shifting its sales mix toward higher-value flower. Management's stated long-term target of roughly $95 per pound in production costs, and the pace of recovery in flower yields, will be key operational metrics. Regulatory developments, including the rescheduling of cannabis and clarity on hemp rules, remain significant catalysts.
Other factors to monitor include fourth-quarter results and margin trends, any resolution of the securities investigation, further auditor-related disclosures, progress on the leadership transition, and the company's ability to generate positive operating cash flow given its fixed debt and preferred-dividend obligations. These items will likely shape sentiment in the months ahead. I’m watching this closely as the next few quarters unfold.
When analyzing volatile names like this, I find it helpful to review automated trading approaches alongside traditional fundamentals. Tickeron’s Trending AI Robots page offers a curated view of AI-driven trading bots that monitor thousands of tickers, including GLAS. The bots vary in strategy, timeframe, and performance metrics, so investors can compare different methods before deciding whether any align with their own objectives. For those tracking names like GLAS, exploring this section can offer additional perspective on how automated strategies are approaching the market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GLAS advanced for three days, in 199 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 28 of 36 cases over the following month. The odds of a continued upward trend are 78%.
GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 73 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for GLAS entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric